[Featured Stock] Dongwha Pharm Hits Upper Limit Following Approval of Phase 2 Clinical Trial Plan for COVID-19 Treatment
[Asia Economy Reporter Minji Lee] Dongwha Pharmaceutical recorded the upper price limit following the news that the Ministry of Food and Drug Safety approved the Phase 2 clinical trial plan for the novel coronavirus disease (COVID-19) treatment.
At 9:57 AM on the 24th, Dongwha Pharmaceutical was trading at 23,600 KRW, up 26.88% from the previous trading day. The company hit the upper price limit of 24,150 KRW during the session.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Trump Warns Iran: "Nothing Will Be Left If They Don't Act Quickly"
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
On the previous day, Dongwha Pharmaceutical received approval for the Phase 2 clinical trial plan of the COVID-19 treatment 'DW2008S.' The Phase 2 trial of 'DW2008S' will evaluate the efficacy and safety in patients with moderate COVID-19.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
